tetano
Editor, Senior Moderator
Transplant Direct
. 2021 Nov 17;7(12):e794.
doi: 10.1097/TXD.0000000000001246. eCollection 2021 Dec.
Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients
Mario Fernández-Ruiz[SUP] 1 2 [/SUP], Patricia Almendro-Vázquez[SUP] 3 [/SUP], Octavio Carretero[SUP] 1 4 [/SUP], Tamara Ruiz-Merlo[SUP] 1 [/SUP], Rocío Laguna-Goya[SUP] 3 [/SUP], Rafael San Juan[SUP] 1 2 [/SUP], Francisco López-Medrano[SUP] 1 2 [/SUP], Estéfani García-Ríos[SUP] 4 [/SUP], Vicente Más[SUP] 4 [/SUP], Miguel Moreno-Batenero[SUP] 3 [/SUP], Carmelo Loinaz[SUP] 5 6 [/SUP], Amado Andrés[SUP] 7 2 [/SUP], Pilar Pérez-Romero[SUP] 4 [/SUP], Estela Paz-Artal[SUP] 3 [/SUP], José María Aguado[SUP] 1 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) elicited by mRNA-based vaccines in solid organ transplant (SOT) recipients and its correlation with antibody responses remain poorly characterized.
Methods: We included 44 (28 kidney, 14 liver, and 2 double organ) recipients who received the full series of the mRNA-1273 vaccine. SARS-CoV-2-CMI was evaluated at baseline, before the second dose, and at 2 wk after completion of vaccination by an ELISpot-based interferon-γ FluoroSpot assay using overlapping peptides covering the S1 domain. SARS-CoV-2 immunoglobulin G seroconversion and serum neutralizing activity against the spike protein were assessed at the same points by commercial ELISA and an angiotensin-converting enzyme-2/spike antibody inhibition method, respectively. Postvaccination SARS-CoV-2-CMI was compared with 28 healthcare workers who received the BNT162b2 vaccine.
Results: Positive SARS-CoV-2-CMI increased from 6.8% at baseline to 23.3% after the first mRNA-1273 dose and 59.5% after the completion of vaccination (P < 0.0001). Lower rates were observed for immunoglobulin G seroconversion (2.3%, 18.6%, and 57.1%, respectively) and neutralizing activity (2.3%, 11.6%, and 31.0%). There was a modest correlation between neutralizing titers and the magnitude of SARS-CoV-2-CMI (Spearman's rho: 0.375; P = 0.015). Fifteen recipients (35.7%) mounted SARS-CoV-2-CMI without detectable neutralizing activity, whereas 3 (7.1%) did the opposite, yielding poor categorical agreement (Kappa statistic: 0.201). Rates of positive SARS-CoV-2-CMI among SOT recipients were significantly decreased compared with nontransplant controls (82.1% and 100.0% after the first dose and completion of vaccination, respectively; P < 0.0001). Kidney transplantation, the use of tacrolimus and prednisone, and the number of immunosuppressive agents were associated with lower cell-mediated responses. Results remained unchanged when 3 recipients with prevaccination SARS-CoV-2-CMI were excluded.
Conclusions: Two-thirds of SOT recipients mounted SARS-CoV-2-CMI following vaccination with mRNA-1273. Notable discordance was observed between vaccine-induced cell-mediated and neutralizing humoral immunities. Future studies should determine whether these patients with incomplete responses are effectively protected.
. 2021 Nov 17;7(12):e794.
doi: 10.1097/TXD.0000000000001246. eCollection 2021 Dec.
Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients
Mario Fernández-Ruiz[SUP] 1 2 [/SUP], Patricia Almendro-Vázquez[SUP] 3 [/SUP], Octavio Carretero[SUP] 1 4 [/SUP], Tamara Ruiz-Merlo[SUP] 1 [/SUP], Rocío Laguna-Goya[SUP] 3 [/SUP], Rafael San Juan[SUP] 1 2 [/SUP], Francisco López-Medrano[SUP] 1 2 [/SUP], Estéfani García-Ríos[SUP] 4 [/SUP], Vicente Más[SUP] 4 [/SUP], Miguel Moreno-Batenero[SUP] 3 [/SUP], Carmelo Loinaz[SUP] 5 6 [/SUP], Amado Andrés[SUP] 7 2 [/SUP], Pilar Pérez-Romero[SUP] 4 [/SUP], Estela Paz-Artal[SUP] 3 [/SUP], José María Aguado[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34805496
- PMCID: PMC8601286
- DOI: 10.1097/TXD.0000000000001246
Abstract
Severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) elicited by mRNA-based vaccines in solid organ transplant (SOT) recipients and its correlation with antibody responses remain poorly characterized.
Methods: We included 44 (28 kidney, 14 liver, and 2 double organ) recipients who received the full series of the mRNA-1273 vaccine. SARS-CoV-2-CMI was evaluated at baseline, before the second dose, and at 2 wk after completion of vaccination by an ELISpot-based interferon-γ FluoroSpot assay using overlapping peptides covering the S1 domain. SARS-CoV-2 immunoglobulin G seroconversion and serum neutralizing activity against the spike protein were assessed at the same points by commercial ELISA and an angiotensin-converting enzyme-2/spike antibody inhibition method, respectively. Postvaccination SARS-CoV-2-CMI was compared with 28 healthcare workers who received the BNT162b2 vaccine.
Results: Positive SARS-CoV-2-CMI increased from 6.8% at baseline to 23.3% after the first mRNA-1273 dose and 59.5% after the completion of vaccination (P < 0.0001). Lower rates were observed for immunoglobulin G seroconversion (2.3%, 18.6%, and 57.1%, respectively) and neutralizing activity (2.3%, 11.6%, and 31.0%). There was a modest correlation between neutralizing titers and the magnitude of SARS-CoV-2-CMI (Spearman's rho: 0.375; P = 0.015). Fifteen recipients (35.7%) mounted SARS-CoV-2-CMI without detectable neutralizing activity, whereas 3 (7.1%) did the opposite, yielding poor categorical agreement (Kappa statistic: 0.201). Rates of positive SARS-CoV-2-CMI among SOT recipients were significantly decreased compared with nontransplant controls (82.1% and 100.0% after the first dose and completion of vaccination, respectively; P < 0.0001). Kidney transplantation, the use of tacrolimus and prednisone, and the number of immunosuppressive agents were associated with lower cell-mediated responses. Results remained unchanged when 3 recipients with prevaccination SARS-CoV-2-CMI were excluded.
Conclusions: Two-thirds of SOT recipients mounted SARS-CoV-2-CMI following vaccination with mRNA-1273. Notable discordance was observed between vaccine-induced cell-mediated and neutralizing humoral immunities. Future studies should determine whether these patients with incomplete responses are effectively protected.